OBJECTIVE: To examine the effects of treatments with niacin or anacetrapib (an inhibitor of cholesteryl ester transfer protein) on the ability of high-density lipoprotein (HDL) to promote net cholesterol efflux and reduce toll-like receptor-mediated inflammation in macrophages. METHODS AND RESULTS: A total of 18 patients received niacin, 2 g/d, for 4 weeks; 20 patients received anacetrapib, 300 mg/d, for 8 weeks; and 2 groups (n=4 and n=5 patients) received placebo. HDL samples were isolated by polyethylene glycol precipitation or ultracentrifugation, tested for the ability to promote cholesterol efflux in cholesterol-loaded THP-I or mouse peritoneal macrophages, or used to pretreat macrophages, followed by lipopolysaccharide exposure. HDL cholesterol levels were increased by 30% in response to niacin and by approximately 100% in response to anacetrapib. Niacin treatment increased HDL-mediated net cholesterol efflux from foam cells, primarily by increasing HDL concentration, whereas anacetrapib treatment increased cholesterol efflux by both increasing HDL concentration and causing increased efflux at matched HDL concentrations. The increased efflux potential of anacetrapib-HDL was more prominent at higher HDL cholesterol concentrations (>12 microg/mL), which was associated with an increased content of lecithin-cholesterol acyltransferase (LCAT) and apolipoprotein E and completely dependent on the expression of ATP binding cassette transporters (ABCA1 and ABCG1). Potent antiinflammatory effects of HDL were observed at low HDL concentrations (3 to 20 microg/mL) and were partly dependent on the expression of ABCA1 and ABCG1. All HDL preparations showed similar antiinflammatory effects, proportionate to the HDL cholesterol concentration. CONCLUSIONS: Niacin treatment caused a moderate increase in the ability of HDL to promote net cholesterol efflux, whereas inhibition of cholesteryl ester transfer protein via anacetrapib led to a more dramatic increase in association with enhanced particle functionality at higher HDL concentrations. All HDLs exhibited potent ability to suppress macrophage toll-like receptor 4-mediated inflammatory responses, in a process partly dependent on cholesterol efflux via ABCA1 and ABCG1.
OBJECTIVE: To examine the effects of treatments with niacin or anacetrapib (an inhibitor of cholesteryl ester transfer protein) on the ability of high-density lipoprotein (HDL) to promote net cholesterol efflux and reduce toll-like receptor-mediated inflammation in macrophages. METHODS AND RESULTS: A total of 18 patients received niacin, 2 g/d, for 4 weeks; 20 patients received anacetrapib, 300 mg/d, for 8 weeks; and 2 groups (n=4 and n=5 patients) received placebo. HDL samples were isolated by polyethylene glycol precipitation or ultracentrifugation, tested for the ability to promote cholesterol efflux in cholesterol-loaded THP-I or mouse peritoneal macrophages, or used to pretreat macrophages, followed by lipopolysaccharide exposure. HDL cholesterol levels were increased by 30% in response to niacin and by approximately 100% in response to anacetrapib. Niacin treatment increased HDL-mediated net cholesterol efflux from foam cells, primarily by increasing HDL concentration, whereas anacetrapib treatment increased cholesterol efflux by both increasing HDL concentration and causing increased efflux at matched HDL concentrations. The increased efflux potential of anacetrapib-HDL was more prominent at higher HDL cholesterol concentrations (>12 microg/mL), which was associated with an increased content of lecithin-cholesterol acyltransferase (LCAT) and apolipoprotein E and completely dependent on the expression of ATP binding cassette transporters (ABCA1 and ABCG1). Potent antiinflammatory effects of HDL were observed at low HDL concentrations (3 to 20 microg/mL) and were partly dependent on the expression of ABCA1 and ABCG1. All HDL preparations showed similar antiinflammatory effects, proportionate to the HDL cholesterol concentration. CONCLUSIONS:Niacin treatment caused a moderate increase in the ability of HDL to promote net cholesterol efflux, whereas inhibition of cholesteryl ester transfer protein via anacetrapib led to a more dramatic increase in association with enhanced particle functionality at higher HDL concentrations. All HDLs exhibited potent ability to suppress macrophage toll-like receptor 4-mediated inflammatory responses, in a process partly dependent on cholesterol efflux via ABCA1 and ABCG1.
Authors: Tomas Vaisar; Subramaniam Pennathur; Pattie S Green; Sina A Gharib; Andrew N Hoofnagle; Marian C Cheung; Jaeman Byun; Simona Vuletic; Sean Kassim; Pragya Singh; Helen Chea; Robert H Knopp; John Brunzell; Randolph Geary; Alan Chait; Xue-Qiao Zhao; Keith Elkon; Santica Marcovina; Paul Ridker; John F Oram; Jay W Heinecke Journal: J Clin Invest Date: 2007-03 Impact factor: 14.808
Authors: Steven E Nissen; Jean-Claude Tardif; Stephen J Nicholls; James H Revkin; Charles L Shear; William T Duggan; Witold Ruzyllo; William B Bachinsky; Gabriel P Lasala; Gregory P Lasala; E Murat Tuzcu Journal: N Engl J Med Date: 2007-03-26 Impact factor: 91.245
Authors: Laurent Yvan-Charvet; Fumihiko Matsuura; Nan Wang; Mark J Bamberger; Tu Nguyen; Franz Rinninger; Xian-Cheng Jiang; Charles L Shear; Alan R Tall Journal: Arterioscler Thromb Vasc Biol Date: 2007-02-22 Impact factor: 8.311
Authors: Maria Pia Adorni; Francesca Zimetti; Jeffrey T Billheimer; Nan Wang; Daniel J Rader; Michael C Phillips; George H Rothblat Journal: J Lipid Res Date: 2007-08-29 Impact factor: 5.922
Authors: Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer Journal: N Engl J Med Date: 2007-11-05 Impact factor: 91.245
Authors: Ronald M Krauss; Kathleen Wojnooski; Joseph Orr; J Casey Geaney; Cathy Anne Pinto; Yang Liu; John A Wagner; Julie Mabalot Luk; Amy O Johnson-Levonas; Matt S Anderson; Hayes M Dansky Journal: J Lipid Res Date: 2011-12-17 Impact factor: 5.922
Authors: Judit Marsillach; Jessica O Becker; Tomas Vaisar; Bevra H Hahn; John D Brunzell; Clement E Furlong; Ian H de Boer; Maureen A McMahon; Andrew N Hoofnagle Journal: J Proteome Res Date: 2015-03-13 Impact factor: 4.466
Authors: Graziella E Ronsein; Patrick M Hutchins; Daniel Isquith; Tomas Vaisar; Xue-Qiao Zhao; Jay W Heinecke Journal: Arterioscler Thromb Vasc Biol Date: 2015-12-17 Impact factor: 8.311